JPH-203 is under clinical development by J-Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect JPH-203’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their JPH-203 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

JPH-203 overview

JPH-203 is under development for the treatment of the solid tumor and biliary tract cancer. It is administered through an intravenous and oral route. The drug candidate is a low molecular weight compound that acts by targeting L-type amino acid transporter1 (LAT1). It was also under development for the treatment of colon cancer.

J-Pharma overview

J-Pharma carries out research and development of pharmaceutical products. J-Pharma is headquartered in Yokohama, Kanagawa, Japan.

Quick View JPH-203 LOA Data

Report Segments
  • Innovator
Drug Name
  • JPH-203
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.